Cardiff Oncology (CRDF) to Release Earnings on Thursday

Key Points

• Q1 2026 earnings are scheduled before the market opens on May 14, 2026 (conference call at 4:00 PM ET); analysts expect EPS of ($0.13) and revenue of $0.089 million.
• In the prior quarter Cardiff topped estimates (EPS ($0.11) vs. consensus ($0.18) and $0.24M revenue), but analysts still project roughly ($1) EPS for the current and next fiscal year.
• Shares trade around $1.68 with a market cap of about $114.9M and a 52-week range of $1.48–$4.56; Wall Street ratings are mixed but the consensus is a “Moderate Buy” with an average price target of $10.10.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) will likely be posting its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Cardiff Oncology to post earnings of ($0.13) per share and revenue of $0.0890 million for the quarter. Individuals may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:00 PM ET.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last announced its earnings results on Tuesday, February 24th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.07. Cardiff Oncology had a negative return on equity of 82.01% and a negative net margin of 7,733.22%.The business had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.13 million. On average, analysts expect Cardiff Oncology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cardiff Oncology Stock Performance

Shares of NASDAQ CRDF opened at $1.68 on Thursday. Cardiff Oncology has a 1 year low of $1.48 and a 1 year high of $4.56. The firm has a market cap of $114.86 million, a price-to-earnings ratio of -2.43 and a beta of 1.36. The stock's 50-day simple moving average is $1.75 and its 200-day simple moving average is $2.11.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Piper Sandler dropped their target price on Cardiff Oncology from $10.00 to $6.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 25th. HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of Cardiff Oncology in a research report on Wednesday, January 28th. Wall Street Zen raised Cardiff Oncology from a "sell" rating to a "hold" rating in a research report on Wednesday, March 4th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Cardiff Oncology in a research report on Wednesday, January 21st. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Cardiff Oncology currently has an average rating of "Moderate Buy" and an average price target of $10.10.

Institutional Trading of Cardiff Oncology

Several hedge funds and other institutional investors have recently bought and sold shares of CRDF. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Cardiff Oncology by 50.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,319 shares of the company's stock valued at $108,000 after buying an additional 11,497 shares during the last quarter. Rhumbline Advisers increased its holdings in Cardiff Oncology by 18.8% in the first quarter. Rhumbline Advisers now owns 63,142 shares of the company's stock valued at $198,000 after buying an additional 9,970 shares during the last quarter. Geode Capital Management LLC increased its holdings in Cardiff Oncology by 7.5% in the second quarter. Geode Capital Management LLC now owns 1,498,838 shares of the company's stock valued at $4,723,000 after buying an additional 104,409 shares during the last quarter. Invesco Ltd. increased its holdings in Cardiff Oncology by 24.9% in the second quarter. Invesco Ltd. now owns 23,795 shares of the company's stock valued at $75,000 after buying an additional 4,749 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in Cardiff Oncology by 23.9% in the second quarter. The Manufacturers Life Insurance Company now owns 21,956 shares of the company's stock valued at $69,000 after buying an additional 4,232 shares during the last quarter. 16.29% of the stock is owned by institutional investors.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff's pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.